JP6862446B2 - 急性の脳または神経損傷の治療または予防の方法 - Google Patents

急性の脳または神経損傷の治療または予防の方法 Download PDF

Info

Publication number
JP6862446B2
JP6862446B2 JP2018527851A JP2018527851A JP6862446B2 JP 6862446 B2 JP6862446 B2 JP 6862446B2 JP 2018527851 A JP2018527851 A JP 2018527851A JP 2018527851 A JP2018527851 A JP 2018527851A JP 6862446 B2 JP6862446 B2 JP 6862446B2
Authority
JP
Japan
Prior art keywords
posiphen
acute
acute brain
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018527851A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018523709A (ja
JP2018523709A5 (enExample
Inventor
マッケキーニ，マリア
Original Assignee
キューアール ファーマ
キューアール ファーマ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キューアール ファーマ, キューアール ファーマ filed Critical キューアール ファーマ
Publication of JP2018523709A publication Critical patent/JP2018523709A/ja
Publication of JP2018523709A5 publication Critical patent/JP2018523709A5/ja
Application granted granted Critical
Publication of JP6862446B2 publication Critical patent/JP6862446B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2018527851A 2015-08-14 2016-08-12 急性の脳または神経損傷の治療または予防の方法 Active JP6862446B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562205431P 2015-08-14 2015-08-14
US62/205,431 2015-08-14
PCT/US2016/046794 WO2017030968A1 (en) 2015-08-14 2016-08-12 Methods of treatment or prevention of acute brain or nerve injuries

Publications (3)

Publication Number Publication Date
JP2018523709A JP2018523709A (ja) 2018-08-23
JP2018523709A5 JP2018523709A5 (enExample) 2019-09-19
JP6862446B2 true JP6862446B2 (ja) 2021-04-21

Family

ID=56801810

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018527851A Active JP6862446B2 (ja) 2015-08-14 2016-08-12 急性の脳または神経損傷の治療または予防の方法

Country Status (9)

Country Link
US (2) US12042482B2 (enExample)
EP (1) EP3334425B1 (enExample)
JP (1) JP6862446B2 (enExample)
CN (1) CN107921024B (enExample)
AU (1) AU2016309815B2 (enExample)
CA (1) CA2994974C (enExample)
DK (1) DK3334425T3 (enExample)
TW (1) TW201717938A (enExample)
WO (1) WO2017030968A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201717938A (zh) 2015-08-14 2017-06-01 Ｑｒ製藥股份有限公司 治療或預防急性腦部或神經損傷的方法
EP3654957A4 (en) 2017-05-24 2021-06-23 Annovis Bio, Inc. PREVENTION OR TREATMENT OF DISEASE CONDITIONS DUE TO METAL DIS-HOMEOSTASIS BY ADMINISTERING POSIPHES TO HEALTHY OR SICK PEOPLE

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171750A (en) 1991-09-26 1992-12-15 The United States Of America As Represented By The Department Of Health And Human Services Substituted phenserines as specific inhibitors of acetylcholinesterase
US5409948A (en) 1992-11-23 1995-04-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for treating cognitive disorders with phenserine
WO1999002154A1 (en) 1997-07-09 1999-01-21 Axonyx Highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias
DE60124730T2 (de) 2000-03-03 2007-10-04 Eisai R&D Management Co., Ltd. Neue methoden unter verwendung von cholinesteraseinhibitoren
WO2002048150A2 (en) 2000-11-02 2002-06-20 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Agents useful for reducing amyloid precursor protein and treating demantia and methods of use thereof
US6495700B1 (en) 2002-01-09 2002-12-17 Axonyx, Inc. Process for producing phenserine and its analog
US20040024043A1 (en) 2002-03-22 2004-02-05 Nigel Greig Method for treating cognitive disorders
WO2004034963A2 (en) 2002-05-17 2004-04-29 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
EP1617844A4 (en) 2003-04-03 2009-07-22 Prana Biotechnology Ltd TREATMENT OF NEUROLOGICAL DISEASES
US20050013869A1 (en) 2003-07-18 2005-01-20 Chaw Cheng Shu Sustained release formulation for carbamates and a method therefor
US20050182044A1 (en) 2004-02-17 2005-08-18 Bruinsma Gosse B. Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate
WO2005091987A2 (en) 2004-03-19 2005-10-06 Axonyx, Inc. Method of treating down syndrome
WO2005089746A1 (en) 2004-03-19 2005-09-29 Axonyx, Inc. Dosage titration for treatment of cognitive disorders
EP1604686A1 (en) 2004-06-08 2005-12-14 Axonyx, Inc. Use of phenserine and a HMG CoA reductase inhibitor for delaying Alzheimer's disease progression
WO2008134618A2 (en) 2007-04-27 2008-11-06 The General Hospital Corporation Novel imaging tracers for early detection and treatment of amyloid plaques caused by alzheimer's disease and related disorders
WO2010117727A2 (en) 2009-03-30 2010-10-14 The General Hospital Corporation Phenserine and posiphen for treating neuropsychiatric and neurodegenerative conditions
US20120225922A1 (en) 2011-03-04 2012-09-06 Qr Pharma Effective Amounts of (3aR)-1,3a,8-Trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo [2,3-b]indol-5-yl Phenylcarbamate and Methods of Treating or Preventing Neurodegeneration
TW201717938A (zh) 2015-08-14 2017-06-01 Ｑｒ製藥股份有限公司 治療或預防急性腦部或神經損傷的方法

Also Published As

Publication number Publication date
CA2994974A1 (en) 2017-02-23
CN107921024B (zh) 2021-09-10
TW201717938A (zh) 2017-06-01
EP3334425B1 (en) 2020-12-16
CA2994974C (en) 2024-04-09
JP2018523709A (ja) 2018-08-23
US20250000846A1 (en) 2025-01-02
DK3334425T3 (da) 2021-02-22
US20180228771A1 (en) 2018-08-16
CN107921024A (zh) 2018-04-17
EP3334425A1 (en) 2018-06-20
HK1253901A1 (en) 2019-07-05
US12042482B2 (en) 2024-07-23
WO2017030968A1 (en) 2017-02-23
AU2016309815B2 (en) 2022-04-07
AU2016309815A1 (en) 2018-02-15

Similar Documents

Publication Publication Date Title
Sivak The aging eye: common degenerative mechanisms between the Alzheimer's brain and retinal disease
US20250000846A1 (en) Methods of treatment or prevention of acute brain or nerve injuries
AU2021396380A1 (en) Compositions for treating dry age-related macular degeneration (amd)
JP2025161811A (ja) タウオパチーを処置するためのペプチド組成物及び方法
JP2024510249A (ja) 神経疾患を治療するための組成物およびその方法
Yanagida et al. Synergistic effect of galantamine on nicotine-induced neuroprotection in hemiparkinsonian rat model
JP2011522017A (ja) ニコチン受容体の部分アゴニストとアセチルコリンエステラーゼ阻害剤との組み合わせ、これらを含有する医薬組成物、および認知障害の処置におけるこれらの使用
US11318122B2 (en) Pharmaceutical combination and its use for treating synucleinopathties
EP3630289A1 (en) Pharmaceutical combinations of zonisamide and praxipexole, and related methods, for treating synucleinopathies
US20250195523A1 (en) Organic molecules for treating myelin pathologies
CN112704678B (zh) 一种丙酰胺衍生物在制备治疗精神分裂症药物中应用
CN1703222A (zh) 使用(2－咪唑啉－2－基氨基)喹噁啉治疗痴呆症和帕金森病的方法
WO2018116293A1 (en) Low dose drug combinations for use in preventing and treating neuronal damage
WO2008098371A1 (en) Compositions and method for reducing amyloid beta in a mammal
HK1253901B (en) Methods of treatment or prevention of acute brain or nerve injuries
US20230372282A1 (en) Method for treateing or preventing ischemic optic neuropathy
CN115212194A (zh) 纳多洛尔在制备治疗缺血/再灌注损伤药物及细胞保护药物中的应用
KR102153648B1 (ko) 산화적 스트레스로부터 성상세포를 보호하는 조성물
CA3096453C (en) Pharmaceutical combination comprising fluoxetine and pramipexole and its use for treating synucleinopathies
WO2022178423A1 (en) Okn-007 as an agent to improve longevity
KR20250065331A (ko) 퇴행성 질환에 의해 유발되는 인지 저하를 예방하기 위한 조성물 및 방법
JP2004531480A (ja) 神経変性疾患の処置のためのトリペプチド誘導体
HK1250489B (en) Substances containing gold clusters and preparation method and use thereof
HK40019782A (en) Agent for preventing or treating brain atrophy
Arshaduddin et al. Ahmad Al Mutairy1, Khalaf Al Moutaery2, Abdulrahman Al Asmari2

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20181029

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20181029

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190809

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190809

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200714

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201012

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210302

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210331

R150 Certificate of patent or registration of utility model

Ref document number: 6862446

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250